Madrigal Pharmaceuticals agreed to acquire six preclinical siRNA programs from Ribo Life Science in a deal with $60 million upfront and as much as $4.4 billion in contingent payments. The programs are intended to complement Madrigal’s Rezdiffra, the first FDA‑approved therapy for metabolic dysfunction‑associated steatohepatitis (MASH). Madrigal said the siRNA assets provide gene‑silencing approaches to address liver‑targeted drivers of MASH and will be developed alongside its THR‑beta agonist franchise. The transaction is heavily back‑loaded on milestones and royalties, reflecting the company’s strategy to build a multi‑program MASH portfolio around an approved anchor therapy.